Biosimilars of low‐molecular‐weight heparin products: fostering competition or reducing ‘biodiversity’?

Summary The term ‘biosimilars’ is used to qualify products developed to be similar to an original biological drug. Biosimilars are much more complicated to develop than a generic version of small‐molecule drugs and this is especially true for low‐molecular‐weight heparins (LMWHs). Evidence on the an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2016-03, Vol.14 (3), p.421-426
Hauptverfasser:	Harenberg, J., Cimminiello, C., Agnelli, G., Di Minno, G., Polo Friz, H., Prandoni, P., Scaglione, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute coronary syndromes Angina pectoris Anticoagulants - adverse effects Anticoagulants - economics Anticoagulants - pharmacokinetics Biodiversity Biological products biosimilar pharmaceuticals Biosimilar Pharmaceuticals - adverse effects Biosimilar Pharmaceuticals - economics Biosimilar Pharmaceuticals - pharmacokinetics Drug Costs Drug Discovery - economics Drug Discovery - methods Drug Industry - economics Economic Competition evidence‐based practise Heart attacks Heparin, Low-Molecular-Weight - adverse effects Heparin, Low-Molecular-Weight - economics Heparin, Low-Molecular-Weight - pharmacokinetics Humans low‐molecular‐weight heparin Male Patient Safety Risk Assessment Risk Factors Therapeutic Equivalency venous thromboembolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!